Skip to main content
. 2017 Oct 6;8(58):98524–98532. doi: 10.18632/oncotarget.21567
22C3
SP263 0-1 1-5 5-10 10-25 25-50 >50 total SP142 0-1 1-5 5-10 10-25 25-50 >50 total E1L3N 0-1 1-5 5-10 10-25 25-50 >50 total
0-1 73 2 0 0 0 0 75 0-1 63 5 4 6 2 2 82 0-1 63 4 3 1 1 1 75
1-5 6 1 0 0 0 0 7 1-5 2 0 0 2 2 4 10 1-5 2 1 1 3 0 0 7
5-10 3 0 0 0 0 0 3 5-10 0 0 0 0 0 2 2 5-10 0 0 0 1 1 1 3
10-25 0 4 0 0 0 0 4 10-25 0 0 0 0 0 2 2 10-25 0 0 0 1 2 1 4
25-50 0 3 0 1 0 0 4 25-50 0 0 0 0 0 1 1 25-50 0 0 0 0 0 4 4
≥50 0 0 2 1 1 0 4 ≥50 0 0 0 0 0 0 0 ≥50 0 0 0 0 0 4 4
total 82 10 2 2 1 0 97 total 65 5 4 8 4 11 97 total 65 5 4 8 4 11 97
SP263
SP142 0-1 1-5 5-10 10-25 25-50 >50 total E1L3N 0-1 1-5 5-10 10-25 25-50 >50 total
0-1 70 3 4 5 0 0 82 0-1 71 2 1 1 0 0 75
1-5 2 0 1 2 3 2 10 1-5 1 1 3 2 0 0 7
5-10 0 0 0 0 1 1 2 5-10 0 0 1 2 0 0 3
10-25 0 0 0 0 2 0 2 10-25 0 0 0 2 2 0 4
25-50 0 0 0 0 0 1 1 25-50 0 0 0 0 2 2 4
≥50 0 0 0 0 0 0 0 ≥50 0 0 0 0 2 2 4
total 72 3 5 7 6 4 97 total 72 3 5 7 6 4 97
E1L3N
SP142 0-1 1-5 5-10 10-25 25-50 >50 total
0-1 73 2 0 0 0 0 75
1-5 6 1 0 0 0 0 7
5-10 3 0 0 0 0 0 3
10-25 0 4 0 0 0 0 4
25-50 0 3 0 1 0 0 4
≥50 0 0 2 1 1 0 4
total 82 10 2 2 1 0 97